Sutro Biopharma

Sutro Biopharma logo
🇺🇸United States
Ownership
Public
Established
2003-01-01
Employees
324
Market Cap
$392.6M
Website
http://www.sutrobio.com
Introduction

Sutro Biopharma, Inc. engages in the drug discovery, development and manufacture of pharmaceutical products. It focuses on the next generation cancer and autoimmune therapeutics. The company was founded by James R. Swartz and Sutanto Widjaja on April 21, 2003 and is headquartered in South San Francisco, CA.

Luveltamab Tazevibulin (STRO-002) in Infants and Children < 12 Years of Age with Relapsed/Refractory CBFA2T3::GLIS2 AML

Phase 1
Recruiting
Conditions
Interventions
First Posted Date
2024-11-07
Last Posted Date
2024-12-17
Lead Sponsor
Sutro Biopharma, Inc.
Target Recruit Count
24
Registration Number
NCT06679582
Locations
🇺🇸

Childrens Hospital of Alabama, Birmingham, Alabama, United States

🇺🇸

Childrens National Hospital, Washington, District of Columbia, United States

🇺🇸

Children's Hospital of Philadelphia (CHOP), Philadelphia, Pennsylvania, United States

and more 1 locations

Study to Investigate Luveltamab Tazevibulin in Adults with Advanced or Metastatic Non-small Cell Lung Cancer

First Posted Date
2024-08-15
Last Posted Date
2024-11-07
Lead Sponsor
Sutro Biopharma, Inc.
Target Recruit Count
43
Registration Number
NCT06555263
Locations
🇺🇸

Tampa General Hospital, Tampa, Florida, United States

🇺🇸

HealthPartners Cancer Research Center, St. Paul, Minnesota, United States

🇺🇸

Florida Cancer Specialists, Lake Mary, Florida, United States

and more 1 locations

REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1

First Posted Date
2023-05-23
Last Posted Date
2024-08-29
Lead Sponsor
Sutro Biopharma, Inc.
Target Recruit Count
600
Registration Number
NCT05870748
Locations
🇺🇸

Texas Oncology, Dallas, Texas, United States

🇺🇸

Ohio State University Center, Columbus, Ohio, United States

🇺🇸

Baptist Health South Florida (BHSF) - Miami Cancer Institute, Miami, Florida, United States

and more 36 locations

A Study of STRO-002, an Anti-Folate Receptor Alpha Antibody Drug Conjugate, in Combination With Bevacizumab in Epithelial Ovarian Cancer

First Posted Date
2022-01-20
Last Posted Date
2024-11-07
Lead Sponsor
Sutro Biopharma, Inc.
Target Recruit Count
58
Registration Number
NCT05200364
Locations
🇺🇸

University of South Florida,, Tampa, Florida, United States

🇺🇸

Thomas Jefferson University, Philadelphia, Pennsylvania, United States

🇺🇸

University of Pennsylvania, Philadelphia, Pennsylvania, United States

and more 3 locations

Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody Drug Conjugate in Ovarian & Endometrial Cancers

First Posted Date
2018-11-20
Last Posted Date
2024-08-01
Lead Sponsor
Sutro Biopharma, Inc.
Target Recruit Count
136
Registration Number
NCT03748186
Locations
🇺🇸

Miami Cancer Institue, Baptist Health South Florida, Miami, Florida, United States

🇺🇸

Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States

🇺🇸

Minnesota Oncology Hematology, Minneapolis, Minnesota, United States

and more 24 locations

Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies

First Posted Date
2018-02-07
Last Posted Date
2024-06-11
Lead Sponsor
Sutro Biopharma, Inc.
Target Recruit Count
70
Registration Number
NCT03424603
Locations
🇺🇸

Texas Oncology - Baylor Charles A. Sammons Cancer Center, Dallas, Texas, United States

🇺🇸

Virginia Cancer Specialists, Fairfax, Virginia, United States

🇺🇸

UT Southwestern Medical Center, Dallas, Texas, United States

and more 19 locations
© Copyright 2024. All Rights Reserved by MedPath